East Tallinn Central Hospital

At East Tallinn Central Hospital, clinical research in the Department of Oncology includes studies focused on ER+/HER2- Early Breast Cancer. These trials are designed to test new treatment strategies and help reduce the risk of cancer recurrence while improving long-term disease control.

• Breast cancer recurrence prevention in ER+/HER2- disease
• Evaluation of newer endocrine-based treatment approaches
• Improving outcomes for people with early-stage breast cancer

This area reflects a strong interest in refining cancer therapy and supporting more effective, personalized care for patients.

The site also supports trials in cardiovascular medicine, with research covering primary prevention of atherosclerotic cardiovascular disease, atrial fibrillation, and heart failure. These studies aim to assess whether new therapies can better prevent serious events such as stroke, heart attack, and worsening heart failure.

• Prevention of major cardiovascular events in high-risk patients
• Stroke and systemic embolism prevention in atrial fibrillation
• Reducing complications in heart failure with inflammation

Research in this field combines cardiology and preventive care to improve safety and outcomes for people at elevated cardiovascular risk.

Clinical trials in ophthalmology at this hospital include treatment studies for macular edema secondary to retinal vein occlusion. The main goal is to determine whether new eye therapies can preserve or improve vision and provide better control of retinal swelling.

• Vision outcomes in macular edema
• Testing improved treatment options for retinal disease
• Assessing the effectiveness and safety of newer ocular therapies

This research supports advances in retinal care and the management of vision-threatening eye conditions.

Research in genetic disorders includes studies on Classic Congenital Adrenal Hyperplasia, a condition linked to hormone imbalance and inherited disease mechanisms. These trials are exploring whether investigational treatments can reduce reliance on standard steroid therapy and better control abnormal hormone levels.

• Lowering glucocorticoid use in congenital adrenal hyperplasia
• Improving hormone control in inherited adrenal disease
• Testing new approaches for a rare genetic condition

This area highlights the hospital’s involvement in rare disease research and in developing more targeted treatment options.

Trials in immune-mediated disease at East Tallinn Central Hospital include studies of Systemic Lupus Erythematosus. The research is aimed at evaluating whether new therapies can better control symptoms, reduce disease activity, and support longer-term safety in people living with this complex inflammatory condition.

• Managing signs and symptoms of Systemic Lupus Erythematosus
• Assessing long-term treatment safety in autoimmune disease
• Improving control of inflammation-related disease activity

This work contributes to broader autoimmune research by seeking more effective options for patients with persistent immune system dysfunction.